Tag Archives: health

Cream of the Launch Crop at Health 2.0

Cream of the Launch Crop at Health 2.0

Text: Eeva Kiuru, Oulu Wellness Institute

The health tech scene is heating and every year there are hundreds of candidate startups running to become the next big health innovation and the best of the Health 2.0 show.

One selection was made today by the Health 2.0 audience. Here are the startups that made it to the Annual Health 2.0 Fall Conference shortlist and Launch main stage:

1. Smart Patient – patient experience and satisfaction service

2. Intellictyx – Intelligent referral service

3. Genetrainer – Gene-based exercise guidance

4. Medlio – Virtual health insurance card focusing on cost transparency

5. Involvecare – Service to get involved with caregiving

6. Wimty – End of life care decision platform (health advocate, life-sustaingin treatments, pain management, wellbeing, final breath) with help of digital process and power of video

7. Recovery record – eating disorder management tool

8. Liviam – Support team platform for hospitalized loved ones

9. Mevoked – Mental health and wellness tracking tool

10. OMSignal – Lifestyle tracker shirt focused on ABC of wellness (Activity, Breathing and Cardiac)

The winner of the Launch competition was voted online by the live audience:  OM Signal Lifestyle tracker shirt.


Introducing New York eHealth Collaborative and Digital Health Accelerator

Introducing New York eHealth Collaborative and Digital Health Accelerator

Text: Eeva Kiuru, Oulu Wellness Institute

OWI’s US Gateway program is on a mission to find Finnish startups different gateways to the US healthcare market. Part of this mission is to recognize important connection points in the US and make sure our developers in Finland are aware of these possibilities. In this miniseries we interview some interesting people we have met during this fall.

September 26, 2013 I had the possibility to visit New York eHealth Collaborative and their Digital Health Accelerator. I met there VP Anuj Desai and Senior Program Manager Yossi Saadon.

Here’s what we discussed:

Eeva: I’m interviewing Yossi Saadon, Senior Program Manager of the Digital Health Accelerator in New York. Hello Yossi.

Yossi: Hi Eeva, how are you ?

Eeva: Great. Please tell me, what exactly is NY eHealth Collaborative and the Digital Health Accelerator ?

Yossi: NY eHealth Collaborative is a non-profit organization with a mission to bring healthcare to all New York through health IT. We break it out into different initiatives. The main thing is to drive the adoption of health IT and electronic health records across New York state.

We also created a state-wide health IT network to allow large hospitals to exchange clinical data with each other. This is the largest clinical network in the USA. We created an API on top of that network to bring innovation and startups to develop and stimulate this ecosystem.

On top of that we developed a New York Digital Health Accelerator program together with our partners, the partnership fund for New York City. This is a 9 month program for health IT startups, usually at the later stage. We require them have a beta and potentially some customers. The companies receive 300.000 usd investment from a group of investors. They have to have a presence in New York during the program.

Our unique differentiator in the program is that we match each of the companies selected to the program with 2-4 provider mentors, so they work with large hospitals in New York State, such as New York Presbyterian Hospital, North Shore LIJ and Mount Sinai. They work with them and receive their mentorship with the goal to get a pilot launched. We had our first class graduated in May 2013. We got 17 pilots launched with the providers and the companies created over 100 jobs in New York City.

Eeva: Sounds great. Can anyone from anywhere in the world apply to your accelerator ?

Yossi: Yes of course. Actually for the first program we received over 250 applications from different states in the US and also from across the world, from England and Israel for example. There is no problem of being part of the program.

Our only condition is to have a presence during the program in New York state. So we just try to attract companies with a hope that eventually they will have enough customers so that they will stay, because we also have an economic mission to create jobs.

Eeva: Do you give funding for the companies and do you take equity of them?

Yossi: Every company accepted into the program receives up to 300.000 usd from a group of investors in a form of a convertible note. First they receive in the beginning of the program 100.000 usd. We have a mid-program check in. All the companies that meet all the requirements receive the additional 200.000 usd.

Our partners, the Partnership fund for New York City, which is a VC with an economic mission to develop the New York, is responsible to a group of investors and they created the fund and can take the equity of the companies.

Eeva: There is a huge development potential in healthcare. Are there any specific domain areas you are looking for when choosing the startups for your accelerator program ? What kind of healthcare problems are you actually trying to fix ?

Yossi: Together with the healthcare providers who are part of our program we have identified four focus areas where there is a need for improvement in healthcare system. The four focus areas are: care coordination, analytics, patient engagement and message alerts. We are looking for companies in each of those specific focus areas to help improve healthcare delivery and reduce costs in those areas.

Eeva: Those are not any small problems you are solving. What are the biggest challenges for health IT startups ? What are they mostly struggling with ?

Yossi: Startups struggle with a lot of different things. It’s admirable to see entrepreneurs come with ideas and driving them forward. I would say the biggest challenge is all about selling. It’s trying to sell what you have. It’s selling to get investors, selling to get customers.

Also the access to customers is very, very challenging if you are a company developing product for healthcare providers because those hospitals have a very slow procurement process. It takes some time to review and get their approval and push it forward. Sometimes it just gets stuck. And just because it gets stuck doesn’t mean that they don’ t need it. Access to providers is very very challenging for startups.

Eeva: Sounds great that you help exactly in those difficult areas. What about investors, are they now active in health IT ?

Yossi: We have eight different investors as part of the program. Some are classic VC’s and some more strategic. There is a lot of excitement in this field, because it’s a changing industry with the Affordable Care Act.

When industry is changing, there is always opportunities for new innovation to come in. When new innovations are about to grow investors want to be part of it and help companies grow and be part of the business development and push it forward. It’s very exciting. This whole market is being stimulated. It’s a great place to be in.

Eeva: Sounds good. Finally, Yossi, we have a very active health IT developer community in Finland. What would you like to say to our developers ?

Yossi: First of all, I admire your drive to become entrepreneurs and developers in any field. I know it’s very very challenging. Keep up. I know sometimes it looks hard. Just do your things right, push forward and things get in the right place.

I invite all of you to come check our program. We offer a lot of tools and needed resources for developers and access to providers. New York State has a lot of large hospitals and health care providers that are eager also to accept those innovations and open-minded to mentoring. That access I want to provide to you guys.

Eeva: Thank you very much, Yossi.

Show your delta

Show your delta

Text and photo: Eeva Kiuru, Oulu Wellness Institute

A team of Finnish Health Tech Startups and support organisations are gathering this week in Santa Clara Silicon Valley for the 7th Annual Health 2.0 Fall Conference.

Special Team Finland program arranged by Tekes and Sitra, kicked off yesterday evening with a team gathering where an experienced group of Silicon Valley Finns (Michel Wendell, Hartti Suomela, Ari Tulla and Nelli Lähteenmäki) shared their insights and secrets to our group.

One thing that grabbed my attention was discussion about delta.

When meeting investors in different matchmaking and pitching sessions, it is important to make a good impression. Who are you ? What are you working on ? What is so special about your new product ? What is your value proposition ? These normal things.

If you are lucky – and if you have done your homework – you may get a chance to continue the talk deeper in your business case.

But according to the Valley Experts, what happens when you meet next time with that same person,  is far more important. What have you done since you last met ? Have you got new clients ? Have you been featured in media ? Have you made improvements to your product ? Have you got funding?

This is delta. This is progress. By showing investors evidence of what you have done since last time you are building trust and far more likely to end up having serious funding discussions.

Terveysteknologian myrskyvaroitus

Terveysteknologian myrskyvaroitus

Teksti ja kuva: Eeva Kiuru

Kirjoittaja on Oulu Wellness Instituuttisäätiön toiminnanjohtaja. Twitter @eevakiuru

Amerikkalainen huippututkija, sähköisen terveydenhuollon pioneerilääkäri Eric Topol
vieraili viime viikolla Helsingissä. Sitran järjestämässä Tulevaisuuden terveys 2020 -seminaarissa yli 600 suomalaista terveydenhuollon asiantuntijaa kuunteli hämmentyneenä, kun Topol vyörytti esityksessään hengästyttävän määrän terveyden innovaatioita, joka tulevat muuttamaan maailmaa.

Digitalisaatio muuttaa rajusti terveydenhuollon toimintamalleja. Yhä enemmän ihmiset itse keräävät mittaustietoja. Tämä on hyvä asia, sillä tunnetusti mitä enemmän ihmiset itse aktiivisesti osallistuvat sairauden hoitoon, sitä parempia ovat myös hoitotulokset. Mittausten
paikkasidonnaisuus häviää. Ketterät etäyhteydet korvaavat valtaosan läsnävastaanotoista.

Lääkäri ei ole enää ainoa tiedon lähde. Hänestä tulee potilaiden kumppani ja valmentaja. Moni lääkäri on varmasti jo nyt ymmällään aktiivisen, mittaustuloksia ja omadiagnooseja mukanaan tuovan potilaan edessä.

Terveysteknologian kehittäjäyhteisöt ovat ennennäkemättömällä vauhdilla alkaneet luoda uusia tuotteita markkinoille. On kiehtovaa, kuinka nopeasti yhteisö on tarttunut erityisesti älypuhelinalustan mahdollisuuksiin. Tärkeimmät elintoiminnot – verenpaineen, verensokerin,
veren happipitoisuuden ja EKG:n – voi jo nyt mitata omatoimisesti älypuhelimen lisälaitteilla.

Kuluttajilla on entistä enemmän mistä valita 50-vuotislahjoja: unimittari, aktiivisuusranneke tai korvavalo. BestBuy-kuluttajaelektroniikkakaupassa on kokonainen osasto mitä erilaisempia
terveyden mittareita. Kuluneen kesän aikana on lanseerattu kymmenittäin uusia terveysteknologiatuotteita vauvojen aktiivisuusmittareista muodikkaisiin kosketusnäyttöisiin terveyskelloihin.

Sokerina pohjalla on IBM:n projekti Watson. Tohtori Supertietokone, joka diagnoosia tehdessään prosessoi 2 miljoonaa sivua potilaskertomuksia alle 3 sekunnissa. Watsonin diagnosointikapasiteetti yhdistettynä kuluttajan älypuhelimiin on aikamoinen tulevaisuuden palvelumalli.

Terveysteknologian kehittäjiltä on tullut myrskyvaroitus. Jos sinulla on terveyteen liittyvä kehittämisidea, sen toteuttamisen aika on juuri nyt.

Kirjoitus on julkaistu 18.9.2013 painetussa ja sähköisessä Oululehdessä.

Health, wellness and life science investors in Europe and USA

Health, wellness and life science investors in Europe and USA

Text by Eeva Kiuru and Veera Virta, Oulu Wellness Institute
Photo by Veera Virta

This is the third blogpost in our series introducing investors in health, wellness and life science. In previous parts we have collected investors in Finland and in Scandinavia. Now it is time to introduce investors in Europe and US. Since corporate venturing has started to play important role is life science investing, we have also included a list of some corporate investors in this domain.


Aberdare Ventures is investing in disruptive digital healthcare companies who aim to cut the unbearable cost of current healthcare. They see new technologies, such as connectivity, analytics, and portability; smart sensors and connected implantables; fast and inexpensive analyses of genes and proteins, the drivers of the change in healthcare. They are located in San Fransisco.

Advent Ventures is a growth and venture capital investor in market-leading tech and life science businesses. Their investments cover a range of sectors within life sciences, including new drug discovery, enabling technologies, med tech and diagnostics. They invest predominantly in early and mid-stage life science companies in Europe and US.

AESCAP is a venture capital company investing in private medical companies in Europe. Their focus is in high-potential companies that work in the fields of diagnosis and treatment of human diseases with realistic product opportunities. The office is in Amsterdam.

Aravis is a Swiss hands-on investor and within life science their focus is on biopharmaceuticals, medical technology and biotechnology companies. They operate in Europe, Asia and North America, with offices in Zurich.

Ariadne Capital is an early-stage investor with a focus on enabling technologies and tools which are transforming established businesses and creating the digital ecosystem of health and lifestyle. They are based in London.

BB Biotech Ventures focuses on emerging companies developing and marketing drugs and medical devices. They primarily focus on product-driven, clinical-stage companies.

Earlybird VC manages over 20 institutional investors’ funds and has invested in over 70
companies. They focus in startups based in Europe and their investment focus areas include medtech. The offices are located in Berlin, Munich and Milano.

Endeavour Vision is a venture and growth capital firm providing expertise and funding to entrepreneurs and companies with global ambitions in life sciences and information technologies. They operate in Europe and US and invest in early to expansion stage companies including spin-offs and restarts.

ED Venture‘s primary activity is investing in and nurturing start-ups, with a focus on health care, human capital and aerospace. Overall, the chairman of ED Ventures, Esther Dyson, is fascinated by new business models, new technologies and new markets (both economically and politically).

Forbion Capital Partners invests in life science and biomedical technology companies that are developing world-class drugs and technologies. They focus in late stage preclinical and early stage clinical product development programs. They have offices in Naarden, Netherlands and Munich, Germany.

Gimv invests in life science, medtech, health and care services companies operating in European market. Offices are in Antwerpen, Paris, Munich and Hague.

Index Ventures is one of the early venture firms in Europe, and they are dedicated to building world-class information technology and life science companies. They invest globally in companies with European focus, and their offices are located in Geneva and London. The initial investments focus in on series A and B rounds.

Khosla Ventures is a high profile investor interested in sevaral disruptive sectors including consumer health. They focus on early stage crazy ideas, black swans and unusual approaches with an unfair competitive advantage in their early and growth phases.

Life Science Partners, LSP, is one of the largest specialized healthcare and biotechnology investment firms. They operate in Europe and US with offices in Amsterdam, Munich and Boston. They invest in variety of areas in healthcare and biotechnology, including drug discovery and development, medical devices, diagnostics, IT-based solutions, industrial biotech and bio materials. The focus in on start-up companies in need of first venture funding but they invest also in later-stages.

Merieux Development is a healthcare investment company. Their main objectives are to identify scientific and technological innovations and support entrepreneurs and companies which potentially will contribute to the medicine of the future. Their target is to have 12 SME’s at different stages of development by 2014 in their portfolio. They operate in Europe, North America, India and China, with office in Lyon, France.

MVM Life Science invests in emerging, early and later stage, healthcare companies with focus on venture capital and growth equity investments. Currently portfolio companies are located in Europe, Israel and US. In life sciences they focus on platforms and products, discovery and development and devices and drugs.

NBGI Ventures is a venture capital fund investing in medical technology companies. Primarily, they invest in EU countries and in companies of all stages from seed to development.

NEA is investor focusing on three key domains—information technology, healthcare and energy technology in the early and growth phases. They operate in US, India and China.

Sofinnova Partners is venture capital firm based in Paris. It invests throughout Europe in life science and clean energy start-ups, early stage companies and corporate spin-offs. It is often the first institutional investor in round A financing.

TPG Biotech is the life science venture investment arm of TPGSM (formerly known as Texas Pacific Group), a global private investment firm. TPG Biotech supports physicians, scientists and entrepreneurs who are building innovation-based businesses in the life sciences. TPG Biotech invests across life science sectors, geographies and stages.

Wellington Partners makes early-stage and growth investments in life science and technology companies. Their focus in life science is in medtech, diagnostics, therapeutics and industrial biotechnology.

Vesalius BioCapital offers venture capital to young, innovative European life science companies and invests human health related companies. The focus is on therapeutics, medical devices, diagnostics, and novel food applications and in companies of all stages of development.

Corporate investors

Ascension Health Ventures (AHV) is a strategic healthcare venture fund with $550 million in capital and nearly 300 acute care hospitals and numerous other healthcare related facilities as limited partners. Besides financial return, investment criteria include fit with strategic priorities of AHV’s limited partners’ health systems and potential to improve clinical outcomes, reduce costs, and/or enhance the experience of patients, families and caregivers. Investment focus is in
healthcare information technology and services, and medical devices and diagnostics.

BlueCross BlueShield Venture Partners (BCBSVP) is corporate venture fund sponsored by the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield companies. The fund invests in technologies, products and services in the healthcare industry that promote efficiency, lower costs, and provide more consumer options. Investments are made from seed through growth stages in US based companies. Focus areas are health IT, informatics, administration and back office, health programs, consumer driven solutions and healthcare finance.

Boehringer Ingelheim Venture Fund’s objective is to search significant enhancements in patient care through innovative and pioneering science. They look globally for groundbreaking therapeutic approaches and technologies that have the potential to advance patient care and meet unmet medical needs. They make initial investments in seed or series A funding.

Merck Global Health Innovation Fund (GHI) is building a portfolio of investments in six focus areas that are outside of Merck’s core pharmaceuticals, vaccines, consumer products, and animal health businesses. GHI’s goal is to grow emerging health care solutions into meaningful businesses. Companies they invest in typically have current revenues, a strong business plan and high growth potential. Focus areas include flexible access, health intervention, personalized medicine, health productivity enablers, health infromatics and analytics and heath data liberation.

Qualcomm Ventures (QCV) is investment arm of Qualcomm Inc. They focus on disruptive early stage companies across a wide range of sectors, including healthcare. Their healthcare focused fund is Qualcomm Life. It specifically focuses on investing in venture-backed wireless health start-ups that will help accelerate the Qualcomm 2net Platform commercialization. The areas of specific interest to the fund range from personal wellness to disease management. Investments are made in areas such as body worn or implantable biosensors or devices for vertically focused applications such as chronic disease care, medication adherence, and fitness or wellness; integrated system providers that do remote diagnosis, monitoring or specialize in independent living; mobile software health IT applications; and health informatics/analytics

West Health Innovation Fund’s mission is to lower health care costs. They invest in companies that are developing health care technologies or services that have the potential to substantially lower the cost of health care delivery. The Fund targets early stage opportunities with a strong preference for pre-commercial and early commercial companies. They invest in innovations in the following areas: advancing cost-effective, cost-saving models of care, creation of efficient medical marketplace, promotion of actionable health care policy and health care data liberation.

This was quite a long list of potential investors. Life science and especially it’s new frontier, digital health and health IT is bubbling right now.  We wanted to do our share and make the funding opprtunities better visible for entrepreneurs. We are sure there are plenty of other investors currently active or becoming active in this field since this is a growth area and many traditional investors are already kicking tires of health tech and health IT.

And by the way, may we recommend you also have a look also at AngelList. There you can find  investors with specific keywords that fit exactly your funding needs.


In the next and final blogpost of this series we will focus on collecting the health tech and life science business accelerators. As always, please comment if we missed something you think should be added here. We would love to hear your comment to make sure this a valuable resource for you.

100 uutta businessideaa

100 uutta businessideaa

Teksti ja kuva: Eeva Kiuru, Oulu Wellness Instituuttisäätiö

Me suomalaiset olemme tunnettuja idearikkaudestamme. Monet tapaamistani yrittäjistä ovat ihmisiä, joilla business-ideoita tipahtelee hihasta jatkuvasti. Ei päivääkään ilman uutta ideaa. He näkevät koko ajan ympärillään asioita, jotka voisi tehdä paremmin.

He yhdistelevät asioita luovasti toisiinsa. He tarttuvat keskustelussa kuulemaansa puolikkaaseen ajatukseen ja liittävät sen johonkin, mitä he olivat jopa vuosia aikaisemmin kokeneet täysin toisessa asiayhteydessä.

Kaikille business-ideoiden keksiminen ei ole yhtä helppoa. Monella olisi halu ryhtyä yrittäjäksi, mutta vain se hyvä idea puuttuu. Mistä niitä mahtavia business-ideoita voisi sitten keksiä?

Kokosin yhteen kolme työkalua, joilla jokainen meistä saa omat ideahanansa avautumaan. Ideat ovat peräsin Stanfordin yliopiston luovuuden ja yrittäjyyden ammattilaisilta oppimistani luovuuden ja innovatiivisuuden harjoittamisen tekniikoista.

1.  Opettele tekemään havaintoja

Kun matkustamme uuteen maahan, jokainen aistimme on hereillä. Seuraamme valppaina ympäristöä, ihmisiä, ääniä – havainnoimme aivan kaikkea. Havaintojen tekeminen jää kuitenkin pian pois. Turrumme nopeasti ääniin, ihmisiin ja rutiineihin.

Kokeile palauttaa havaintokykysi. Havainnoi arkista ympäristöä kuin olisit turisti, joka on ensimmäistä kertaa kohteessa. Saatat huomata mutkikkaita itsestäänselvyyksiä, ja sinulle voi herätä kysymys, voisiko tuon asian tehdä toisin?

2.  Etsi ongelmia, älä vielä ratkaisuja

Parhaat business-ideat ratkaisevat todellisia ongelmia. Siksi kannattaa lähteä liikkeelle etsimällä todellisia, isoja ja kalliiksi tulevia ongelmia. Kun seuraavan kerran käyt sairaalassa tai terveyskeskuksessa, kokeile havainnoida ongelmia.

Tarkkaile asiakkaita, potilaita, työntekijöitä. Huomaatko turhia työvaiheita, vaaratilanteita, toistoja, odottelua tai asioita, joita voisit tehdä vaikka itse? Varaa havaintojen tekemiseen oma pieni vihko, johon voit kirjoittaa kaikkea mitä huomaat. Myös yksinkertaisilta tuntuvia asioita kannattaa kirjata ylös.

3. Kirjaa ylös 100 ratkaisua

Aivan oikein. Sata. Jokainen meistä pystyy listaamaan helposti muutaman melko tavanomaisen ehdotuksen esitettyyn ongelmaan. Mutta kokeilepa keksiä sata ratkaisuehdotusta johonkin pulmaan. Se vaatiikin jo eri lailla luovuutta ja uutta ajattelua.

Joudut menemään epämukavuusalueelle ja yhdistelemään toisiinsa kuulumattomia asioita. Joudut heittäytymään lapselliseksi, ja laittaa mielikuvituksesi lentoon. Joudut ehkä ottamaan muita´mukaan ideoimaan ratkaisua. Ehkä kysyt ohimennen ratkaisua vaikka 10-vuotiaalta
lapselta. Hän on onnellisen tietämätön ideointisi vakavuudesta ja kaikista keksityistä rajoitteista ja heittää estottomasti villejä ideoita ongelman ratkaisemiseksi.

Aurinkoista ja idearikasta kevättä !

Kirjoitus on julkaistu Oululehdessä 15.5.2013

Terveysteknologian vienti ja kauppatase ennätyslukemiin

Suomen terveysteknologian
teollisuuden vienti vuonna 2012 kasvoi 22,8 prosenttia edelliseen vuoteen
verrattuna ja oli arvoltaan yhteensä 1,65 miljardia euroa. Kauppataseen
ylijäämä kasvoi 735 miljoonaan euroon, mikä on 44 prosenttia edellisvuotta
enemmän. Näillä luvuilla terveysteknologia tuottaa nyt 38 prosenttia Suomen
korkean teknologian viennistä ja on jo jonkin aikaa ollut Suomen toiseksi
suurin korkean teknologian vientiala telekommunikaation jälkeen.

Terveysteknologian Liitto ry FiHTAn toiminnanjohtaja Terhi Kajaste sanoo, että terveysteknologia on tällä hetkellä suomalaiselle teollisuudelle ja kansantaloudelle vieläkin tärkeämpi  kuin numerot osoittavat.

”Tarvitsemme tällaista vahvasti kasvavaa toimialaa nyt, kun lähes koko muu teollisuus sukeltaa ja kauppatase on kääntynyt negatiiviseksi. Terveysteknologia edustaa kaikkea sitä, mitä Suomessa olevalta, tänne syntyvältä ja tänne tulevalta yritystoiminnalta toivotaan:  kasvua, kansainvälisyyttä, innovatiivisuutta, huippuosaamista ja pysyvyyttä”, Kajaste sanoo.

”Terveysteknologia on myös siitä harvinainen ala, että tuotteita kannattaa valmistaa ja koota Suomessa. Monilla muilla aloilla tuotanto siirtyy enenevässä määrin Suomesta pois. Terveysteknologia työllistääkin jo yli 10.000 henkeä.”

FiHTAn puheenjohtaja, Innokas Medical Oy:n toimitusjohtaja Jouni Ihme kertoo, että FiHTA on
julkaissut hiljattain kannanoton, jossa esitellään toimenpiteitä terveysteknologian toimintaedellytysten kehittämiseksi. Julkilausuma on luovutettu työ- ja elinkeinoministeriölle otettavaksi huomioon, kun maamme teollisuuspoliittisia linjanvetoja tehdään.

”Kiinnitämme julkilausumassa huomiota muun muassa rahoituksen turvaamiseen, sillä terveysteknologian tuotteiden kehittäminen kaupallisiksi tuotteiksi kestää poikkeuksellisen kauan. Haluamme myös kehittää yhteistyötä yliopistollisten sairaaloiden kanssa. Uhkana
on, että kun hoitopuolen resurssien tarve kasvaa, yo-sairaaloiden resursseja aletaan ohjata tutkimuksesta ja kehittämisestä hoitotyöhön”, Jouni Ihme sanoo.

Terveysteknologia kasvoi vuonna 2012 kaikilla osa-alueilla. Erityisen voimakasta kasvu oli sähkökäyttöisissä terveydenhuollon laitteissa ja kuvantamislaitteissa. Maantieteellisesti vienti
kasvoi eniten USA:han, Venäjälle ja Aasiaan. Euroopassa kasvua oli jonkin verran.

Terveysteknologian vienti on kasvanut viimeisten viiden vuoden aikana keskimäärin 8,1 prosenttia ja kauppataseen ylijäämä keskimäärin 13,6 prosenttia. Kauppataseen ylijäämä nousi
vuonna 2012 ennätykselliseksi siitä huolimatta, että terveysteknologian tuonti Suomeen kasvoi voimakkaasti.

Suomen terveysteknologian teollisuus jakautuu selvästi muutamaan globaaliin suureen yritykseen sekä lukuisiin pieniin ja keskisuuriin kasvuyrityksiin. Suurimmat toimijat ovat usein
kansainvälisten konsernien Suomessa toimivia tytäryhtiötä. Poikkeuksen muodostaa edelleen vahvasti suomalaisessa omistuksessa oleva Planmeca Group.

”Ala ei siis ole homogeeninen ja kasvun haasteet ovat yrityksissä erilaisia. Yritykset pitävät kuitenkin tulevaisuuden näkymiä hyvinä, sillä markkinat kasvavat edelleen. Ammattitaitoisen työvoiman saatavuutta pidetään merkittävimpänä uhkana kasvulle”, Terhi Kajaste sanoo.


–  Terveysteknologian kauppatase 2012. Erityisasiantuntija Sean Donovanin raportti

–  Terveysteknologian kasvustrategian jalkauttamisen aika. FiHTAn julkilausuma terveysteknologian teollisuudenalan toimintaedellytysten kehittämisestä

–  www.fihta.fi

–  www.finnishhealthtech.fi

–  Toiminnanjohtaja Terhi Kajaste, 050 576 5536, terhi.kajaste@teknologiateollisuus.fi,

–  Puheenjohtaja Jouni Ihme, 0400 689 824, jouni.ihme@innokasmedical.fi

Oulu Wellness Institute (OWI) on voittoa tavoittelematon säätiö, joka kehittää hyvinvointialan liiketoimintaosaamista, edistää toimialan kansallista ja kansainvälistä kasvua sekä aktivoi alan eri toimijoiden välistä yhteistyötä.

OWIn toiminta on osa Työ- ja elinkeinoministeriön rahoittamaa OSKE Hyvinvinvoinnin klusteriohjelmaa.